(RTTNews) - Mahwah, New Jersey-based Glenmark Pharmaceuticals Inc., USA is recalling 114 batches of Potassium Chloride Extended-Release Capsules USP (750 mg) 10 mEq K citing failed dissolution, ...

Amneal to hold CREXONT launch symposium and scientific presentations at the International Congress of Parkinson’s Disease and Movement Disorders on Sept. 27 – Oct. 1, 2024 BRIDGEWATER, N.J.--(BUSINESS ...

Please provide your email address to receive an email when new articles are posted on . Crexont was associated with about a half an hour more of “good on” time per day compared with immediate release ...

Phase 4 ELEVATE-PD interim data from the entire study population (n=214) continue to show clinically meaningful, consistent benefits of CREXONT ...

Please provide your email address to receive an email when new articles are posted on . The FDA has granted tentative approval to Zydus Pharmaceuticals Inc. to market extended-release capsules of ...

Jornay PM (methylphenidate) is a prescription drug for treating attention deficit hyperactivity disorder (ADHD) in adults and some children. The drug comes as an oral capsule that’s taken once daily.

MUMBAI, India & NAPLES, Fla., Feb. 4, 2026 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced the launch of ...

Treatment with Crexont statistically significantly improved “On” time without troublesome dyskinesia compared with carbidopa/levodopa IR. The Food and Drug Administration (FDA) has approved Crexont ® ...

A total of 135 batches of potassium chloride capsules have been recalled because the extended release capsules might not release. Glenmark Laboratories recalled 114 batches of 750 mg Potassium ...

Hydrocodone is a generic prescription medication used to treat severe pain. It’s approved for severe pain that needs daily, around-the-clock, long-term treatment with an opioid. Hydrocodone is only ...

Allergan plc (NYSE: AGN), today announced that its subsidiaries Forest Laboratories, LLC and Forest Laboratories Holdings, Ltd., along with Adamas Pharmaceuticals, Inc., have entered into a settlement ...

Phase 3 Adult Laboratory Classroom study confirmed that Adhansia XR provided rapid and sustained symptom relief for up to 16 hours in adults diagnosed with ADHD with a safety profile similar to ...